(Q32031896)

5 July 2017

1 reference

title

Recombinant antibody fragments (English)

1 reference

5 July 2017

1 reference

Hudson PJ

1

1 reference

5 July 2017

publication date

1 August 1998

1 reference

Current Opinion in Biotechnology

5 July 2017

published in

1 reference

5 July 2017

volume

9

1 reference

5 July 2017

issue

4

1 reference

5 July 2017

page(s)

395-402

1 reference

Engineering antibodies for imaging and therapy

5 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

1 reference

7 January 2021

VL:VH domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Antibody phage display technology and its applications.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Phage display of combinatorial antibody libraries.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Antibody humanization using monovalent phage display

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

New protein engineering approaches to multivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Effects of substitutions in the binding surface of an antibody on antigen affinity

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Comparison of fusion phage libraries displaying VH or single-chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma-specific targeting molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Heavy chain CDR3 optimization of a germline encoded recombinant antibody fragment predisposed to bind the U1A protein

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Site-specific mutagenesis of a recombinant anti-single-stranded DNA Fab. Role of heavy chain complementarity-determining region 3 residues in antigen interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Immune versus natural selection: antibody aldolases with enzymic rates but broader scope

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Electrostatic complementarity at protein/protein interfaces

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Selection and identification of single domain antibody fragments from camel heavy-chain antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Structural insights into the evolution of an antibody combining site

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Identification of framework residues in a secreted recombinant antibody fragment that control production level and localization in Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Novel selection method for engineered antibodies using the mechanism of Fv fragment stabilization in the presence of antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

X-ray crystallography reveals stringent conservation of protein fold after removal of the only disulfide bridge from a stabilized immunoglobulin variable domain

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Intracellular antibodies (intrabodies) for gene therapy of infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Inhibition of murine leukaemia virus retrotranscription by the intracellular expression of a phage-derived anti-reverse transcriptase antibody fragment

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Triabodies: single chain Fv fragments without a linker form trivalent trimers

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Enzyme immunoassays using bispecific diabodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Mammalian cell expression of dimeric small immune proteins (SIP).

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Retargeting serum immunoglobulin with bispecific diabodies

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Complement recruitment using bispecific diabodies

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Erratum: Activation of complement by an IgG molecule without a genetic hinge

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Cloning and cytotoxicity of a human pancreatic RNase immunofusion

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Tumor-specific T-bodies: towards clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

A fluoroimmunoassay based on immunoliposomes containing genetically engineered lipid-tagged antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Single-chain Fv fusion proteins suitable as coating and detecting reagents in a double antibody sandwich enzyme-linked immunosorbent assay

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

In vitro selection and evolution of functional proteins by using ribosome display

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Use of mutator cells as a means for increasing production levels of a recombinant antibody directed against Hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Molecular evolution by staggered extension process (StEP) in vitro recombination

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Cloning and expression of human V-genes derived from phage display libraries as fully assembled human anti-TNF alpha monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Selective phage infection mediated by epitope expression on F pilus

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Affinity and folding properties both influence the selection of antibodies with the selectively infective phage (SIP) methodology.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Selectively-infective phage (SIP): a mechanistic dissection of a novel in vivo selection for protein-ligand interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2898%2980014-1

7 January 2021

10.1016/S0958-1669(98)80014-1

Identifiers

DOI

1 reference

5 July 2017

1 reference